Global WholeHealth Partners Corp. (OTC:GWHP), a multinational supplier of over 70+ FDA approved tests including Dengue, Ebola, Zika, Malaria and also offering one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2. With the vaccine rollout in progress, continued testing for COVID-19 is imperative and needs to remain a top priority to stop the spread of this deadly virus. Global WholeHealth Partners, Corp (OTC:GWHP) Secures Distribution Rights to sell the AstraZeneca COVID-19 Vaccine anywhere in the world pending FDA Approval as Biden Administration Increases Stockpile in preparation of a quick roll out. Charles Strongo, CEO of Global WholeHealth Partners, Corp., said, “We were so impressed by the progress that AstraZeneca has made thus far with their vaccine, that we (Global) have acquired the distribution rights to sell this vaccine anywhere in the world.”   “We think the Biden Administration is being strategically proactive with their plan to accumulate the AstraZeneca vaccines ahead of time,” Charles Strongo commented. White House press secretary Jen Psaki recently said, “We want to be oversupplied and overprepared,” saying Biden wanted contingencies in the event of any unforeseen issues with the existing production timeline. A copy   Read more…